Compare Natera Inc. Common Stock (NTRA) vs Stitch Fix Inc (SFIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Stitch Fix Inc — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Stitch Fix Inc trades at $2.38 (market cap $326.66M). The key difference: Natera Inc. Common Stock is far larger — about 174.6× Stitch Fix Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Stitch Fix Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Stitch Fix Inc for 31 Days on average.
| NTRA | SFIX | |
|---|---|---|
Market Cap | $57.03B | $326.66M |
Volume | 1,131,157 | 3,004,657 |
Sector | Health | Consumer Cyclical |
52-Week High | $425.64 | $5.64 |
52-Week Low | $179.42 | $2.16 |
Typical Hold Time | 0 Days | 31 Days |
Enterprise Value | $56.18B | $222.46M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Stitch Fix (SFIX) trades at $2.39, down 11.48% amid bearish technical signals and negative cash flow trends. The company shows improving fundamentals with three consecutive quarterly EPS beats and narrowing losses, though revenue remains stagnant at $1.27B. Recent news highlights fraud investigations and disappointing Q4 2026 results that missed revenue estimates, driving the stock's decline.
The outlook remains challenging with analyst consensus leaning neutral (69.7% hold) and a $3.40 price target suggesting limited upside. Key risks include ongoing legal scrutiny, weak FY27 guidance, and persistent net losses despite margin improvements. The stock's trajectory depends on reversing active client declines and achieving sustainable profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Stitch Fix Inc
Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.
Read more on SFIX →
